Increased tissue perfusion promotes capillary dysplasia in the ALK1-deficient mouse brain following VEGF stimulation

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 295, Issue 6, 2008, Pages

  Hao, Qi ^a   Su, Hua ^b   Marchuk, Douglas A ^c   Rola, Radoslaw ^a   Wang, Yongqiang ^a   Liu, Weizhong ^a   Young, William L ^a   Yang, Guo Yuan ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Activin receptor like kinase 1; Angiogenesis; Vascular endothelial growth factor

Indexed keywords

ACTIVIN RECEPTOR LIKE KINASE 1; ANGIOGENIC FACTOR; BETA GALACTOSIDASE; HYDRALAZINE; NICARDIPINE; PARVOVIRUS VECTOR; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN ARTERIOVENOUS MALFORMATION; BRAIN BLOOD FLOW; BRAIN CAPILLARY; CONTROLLED STUDY; DYSPLASIA; GENE TRANSFER; LOSS OF FUNCTION MUTATION; MALE; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RENDU OSLER WEBER DISEASE; TISSUE PERFUSION;

ACTIVIN RECEPTORS, TYPE I; ANIMALS; BRAIN; CAPILLARIES; CEREBROVASCULAR CIRCULATION; DEPENDOVIRUS; DISEASE MODELS, ANIMAL; GENETIC VECTORS; HYDRALAZINE; IMAGING, THREE-DIMENSIONAL; INFUSIONS, PARENTERAL; INTRACRANIAL ARTERIOVENOUS MALFORMATIONS; MALE; MICE; MICE, KNOCKOUT; MICROCIRCULATION; MICROSCOPY, CONFOCAL; NEOVASCULARIZATION, PHYSIOLOGIC; NICARDIPINE; TRANSDUCTION, GENETIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASODILATOR AGENTS;

EID: 57349194269     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00083.2008     Document Type: Article

References (50)

1. Auer LM, Sayama I, Johansson BB. Cerebrovascular effects of dihydralazine in hypertensive and normotensive rats. Acta Med Scand Suppl 678: 73-81, 1983.
2. Barry DI, Strandgaard S, Graham DI, Svendsen UG, Braendstrup O, Paulson OB. Cerebral blood flow during dihydralazine-induced hypotension in hypertensive rats. Stroke 15: 102-107, 1984.
3. Berg JN, Gallione CJ, Stenzel TT, Johnson DW, Allen WP, Schwartz CE, Jackson CE, Porteous ME, Marchuk DA. The activin receptor-like kinase 1 gene: genomic structure and mutations in hereditary hemorrhagic telangiectasia type 2. Am J Hum Genet 61: 60-67, 1997.
4. Bhardwaj S, Roy H, Gruchala M, Viita H, Kholova I, Kokina I, Achen MG, Stacker SA, Hedman M, Alitalo K, Yla-Herttuala S. Angiogenic responses of vascular endothelial growth factors in periadventitial tissue. Hum Gene Ther 14: 1451-1462, 2003.
5. Bourdeau A, Cymerman U, Paquet ME, Meschino W, McKinnon WC, Guttmacher AE, Becker L, Letarte M. Endoglin expression is reduced in normal vessels but still detectable in arteriovenous malformations of patients with hereditary hemorrhagic telangiectasia type 1. Am J Pathol 156: 911-923, 2000.
6. Chan CY, Chen YS, Ma MC, Chen CF. Remodeling of experimental arteriovenous fistula with increased matrix metalloproteinase expression in rats. J Vasc Surg 45: 804-811, 2007.
7. Chen Y, Fan Y, Poon KY, Achrol AS, Lawton MT, Zhu Y, McCulloch CE, Hashimoto T, Lee C, Barbaro NM, Bollen AW, Yang GY, Young WL. MMP-9 expression is associated with leukocytic but not endothelial markers in brain arteriovenous malformations. Front Biosci 11: 3121-3128, 2006.
8. Chen YG, Massague J. Smad1 recognition and activation by the ALK1 group of transforming growth factor-beta family receptors. J Biol Chem 274: 3672-3677, 1999.
9. Chien S. Mechanotransduction and endothelial cell homeostasis: the wisdom of the cell. Am J Physiol Heart Circ Physiol 292: H1209-H1224, 2007.
10. David L, Mallet C, Vailhe B, Lamouille S, Feige JJ, Bailly S. Activin receptor-like kinase 1 inhibits human microvascular endothelial cell migration: potential roles for JNK and ERK. J Cell Physiol 213: 484-489, 2007.
11. Dirnagl U, Kaplan B, Jacewicz M, Pulsinelli W. Continuous measurement of cerebral cortical blood flow by laser-Doppler flowmetry in a rat stroke model. J Cereb Blood Flow Metab 9: 589-596, 1989.
12. Dumont O, Loufrani L, Henrion D. Key role of the NO-pathway and matrix metalloprotease-9 in high blood flow-induced remodeling of rat resistance arteries. Arterioscler Thromb Vasc Biol 27: 317-324, 2007.
13. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 146: 1029-1039, 1995.
14. Fleetwood IG, Steinberg GK. Arteriovenous malformations. Lancet 359: 863-873, 2002.
15. Guttmacher AE, Marchuk DA, White RI. Hereditary hemorrhagic telangiectasia. N Engl J Med 333: 918-924, 1995.
16. Hao Q, Chen Y, Zhu Y, Fan Y, Palmer D, Su H, Young WL, Yang GY. Neutrophil depletion decreases VEGF-induced focal angiogenesis in the mature mouse brain. J Cereb Blood Flow Metab 27: 1853-1860, 2007.
17. Harper SL. Effects of antihypertensive treatment on the cerebral microvasculature of spontaneously hypertensive rats. Stroke 18: 450-456, 1987.
18. Hashimoto T, Lam T, Boudreau NJ, Bollen AW, Lawton MT, Young WL. Abnormal balance in the angiopoietin-tie2 system in human brain arteriovenous malformations. Circ Res 89: 111-113, 2001.
19. Hashimoto T, Mesa-Tejada R, Quick CM, Bollen AW, Joshi S, Pile-Spellman J, Lawton MT, Young WL. Evidence of increased endothelial cell turnover in brain arteriovenous malformations. Neurosurgery 49: 124-131, 2001.
20. Hashimoto T, Wen G, Lawton MT, Boudreau NJ, Bollen AW, Yang GY, Barbaro NM, Higashida RT, Dowd CF, Halbach VV, Young WL. Abnormal expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in brain arteriovenous malformations. Stroke 34: 925-931, 2003.
21. Hashimoto T, Wu Y, Lawton MT, Yang GY, Barbaro NM, Young WL. Co-expression of angiogenic factors in brain arteriovenous malformations. Neurosurgery 56: 1058-1065, 2005.
22. Janssen BJ, De Celle T, Debets JJ, Brouns AE, Callahan MF, Smith TL. Effects of anesthetics on systemic hemodynamics in mice. Am J Physiol Heart Circ Physiol 287: H1618-H1624, 2004.
23. Johansson BB. Blood-brain barrier dysfunction in acute arterial hypertension after papaverine-induced vasodilatation. Acta Neurol Scand 50: 573-580, 1974.
24. Johansson BB, Auer LM, Trummer UG. Pial vascular reaction to intravenous dihydralazine in the cat. Stroke 11: 369-371, 1980.
25. Johnson DW, Berg JN, Baldwin MA, Gallione CJ, Marondel I, Yoon SJ, Stenzel TT, Speer M, Pericak-Vance MA, Diamond A, Guttmacher AE, Jackson CE, Attisano L, Kucherlapati R, Porteous ME, Marchuk DA. Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2. Nat Genet 13: 189-195, 1996.
26. Joshi S, Young WL, Pile-Spellman J, Duong DH, Vang MC, Hacein-Bey L, Lee HT, Ostapkovich ND. The feasibility of intracarotid adenosine for the manipulation of human cerebrovascular resistance. Anesth Analg 87: 1291-1298, 1998.
27. Koizumi T, Shiraishi T, Hagihara N, Tabuchi K, Hayashi T, Kawano T. Expression of vascular endothelial growth factors and their receptors in and around intracranial arteriovenous malformations. Neurosurgery 50: 117-124, 2002.
28. Lamouille S, Mallet C, Feige JJ, Bailly S. Activin receptor-like kinase 1 is implicated in the maturation phase of angiogenesis. Blood 100: 4495-4501, 2002.
29. Lee CZ, Xue Z, Zhu Y, Yang GY, Young WL. Matrix metalloproteinase-9 inhibition attenuates vascular endothelial growth factor-induced intracranial hemorrhage. Stroke 38: 2563-2568, 2007.
30. Lee RJ, Springer ML, Blanco-Bose WE, Shaw R, Ursell PC, Blau HM. VEGF gene delivery to myocardium: deleterious effects of unregulated expression. Circulation 102: 898-901, 2000.
31. Macias-Silva M, Hoodless PA, Tang SJ, Buchwald M, Wrana JL. Specific activation of Smad1 signaling pathways by the BMP7 type I receptor, ALK2. J Biol Chem 273: 25628-25636, 1998.
32. Marchuk DA, Srinivasan S, Squire TL, Zawistowski JS. Vascular morphogenesis: tales of two syndromes. Hum Mol Genet 12: R97-R112, 2003.
33. Oh SP, Seki T, Goss KA, Imamura T, Yi Y, Donahoe PK, Li L, Miyazono K, ten Dijke P, Kim S, Li E. Activin receptor-like kinase 1 modulates transforming growth factor-beta 1 signaling in the regulation of angiogenesis. Proc Natl Acad Sci USA 97: 2626-2631, 2000.
34. Overgaard J, Skinhoj E. A paradoxical cerebral hemodynamic effect of hydralazine. Stroke 6: 402-404, 1975.
35. Rissanen TT, Rutanen J, Yla-Herttuala S. Gene transfer for therapeutic vascular growth in myocardial and peripheral ischemia. Adv Genet 52: 117-164, 2004.
36. Schroeder T, Sillesen H. Dihydralazine induces marked cerebral vasodilation in man. Eur J Clin Invest 17: 214-217, 1987.
37. Schwarz ER, Speakman MT, Patterson M, Hale SS, Isner JM, Kedes LH, Kloner RA. Evaluation of the effects of intramyocardial injection of DNA expressing vascular endothelial growth factor (VEGF) in a myocardial infarction model in the rat - angiogenesis and angioma formation. J Am Coll Cardiol 35: 1323-1330, 2000.
38. Shen F, Fan Y, Su H, Zhu Y, Chen Y, Liu W, Young WL, Yang GY. Adeno-associated viral vector-mediated hypoxia-regulated VEGF factor gene transfer promotes angiogenesis following focal cerebral ischemia in mice. Gene Ther 15: 30-39, 2008.
39. Shen F, Su H, Liu W, Kan YW, Young WL, Yang GY. Recombinant adeno-associated viral vector encoding human VEGF165 induces neomicrovessel formation in the adult mouse brain. Front Biosci 11: 3190-3198, 2006.
40. Shenkar R, Elliott JP, Diener K, Gault J, Hu LJ, Cohrs RJ, Phang T, Hunter L, Breeze RE, Awad IA. Differential gene expression in human cerebrovascular malformations. Neurosurgery 52: 465-478, 2003.
41. Shovlin CL, Guttmacher AE, Buscarini E, Faughnan ME, Hyland RH, Westermann CJ, Kjeldsen AD, Plauchu H. Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). Am J Med Genet 91: 66-67, 2000.
42. Springer ML, Chen AS, Kraft PE, Bednarski M, Blau HM. VEGF gene delivery to muscle: potential role for vasculogenesis in adults. Mol Cell 2: 549-558, 1998.
43. Srinivasan S, Hanes MA, Dickens T, Porteous ME, Oh SP, Hale LP, Marchuk DA. A mouse model for hereditary hemorrhagic telangiectasia (HHT) type 2. Hum Mol Genet 12: 473-482, 2003.
44. Sure U, Butz N, Siegel AM, Mennel HD, Bien S, Bertalanffy H. Treatment-induced neoangiogenesis in cerebral arteriovenous malformations. Clin Neurol Neurosurg 103: 29-32, 2001.
45. 2+-antagonist. Jpn J Pharmacol 32: 665-670, 1982.
46. Taupin P. BrdU immunohistochemistry for studying adult neurogenesis: paradigms, pitfalls, limitations, and validation. Brain Res Rev 53: 198-214, 2007.
47. Urness LD, Sorensen LK, Li DY. Arteriovenous malformations in mice lacking activin receptor-like kinase-1. Nat Genet 26: 328-331, 2000.
48. Xu B, Wu YQ, Huey M, Arthur HM, Marchuk DA, Hashimoto T, Young WL, Yang GY. Vascular endothelial growth factor induces abnormal microvasculature in the endoglin heterozygous mouse brain. J Cereb Blood Flow Metab 24: 237-244, 2004.
49. Zhang ZG, Zhang L, Jiang Q, Zhang R, Davies K, Powers C, Bruggen N, Chopp M. VEGF enhances angiogenesis and promotes blood-brain barrier leakage in the ischemic brain. J Clin Invest 106: 829-838, 2000.
50. Zhu W, Fan Y, Frenzel T, Gasmi M, Bartus RT, Young WL, Yang GY, Chen Y. Insulin growth factor-1 gene transfer enhances neurovascular remodeling and improves long-term stroke outcome in mice. Stroke 39: 1254-1261, 2008.